Role of PET/PET-CT in the management of sarcomas

Rakesh Kumar, Anil Chauhan, Ananth Kesav Vellimana, Madhavi Chawla

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Positron emission tomography (PET) is a functional diagnostic imaging technique that provides very different information from that obtainable with other imaging modalities. The most widely used radiotracer is F-18 fluoro-2-deoxy-D-glucose (FDG), which is an analog of glucose. The FDG uptake in cells is directly proportional to glucose metabolism, which is increased many times in malignant cells. FDG-PET is now the standard of care in initial staging, monitoring the response to therapy and management of various cancers (e.g., breast cancer, lung cancer and lymphoma). However, the paucity of anatomical landmarks on PET images makes a consistent hardware fusion to anatomical cross-sectional data extremely useful. The introduction of combined PET-computer tomography (CT) scanners, which provide not only functional, but also structural information leading to a detection of subcentimeter lesions, made this technique useful in the early detection of the disease process and decreasing false-positive lesions. The aim of this article is to review the clinical applications (i.e., diagnosis, staging, evaluation of treatment response and restaging) using PET in patients with bone and soft-tissue sarcoma.

Original languageEnglish
Pages (from-to)1241-1250
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number8
StatePublished - Aug 2006


  • Bone sarcoma
  • Bone tumors
  • Oncology
  • PET-CT
  • Soft-tissue sarcoma


Dive into the research topics of 'Role of PET/PET-CT in the management of sarcomas'. Together they form a unique fingerprint.

Cite this